Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23 2024 - 8:17AM
Business Wire
Mythic Therapeutics, a clinical-stage biotechnology company
committed to the development of next-generation antibody-drug
conjugate (ADC) therapies for the treatment of a wide range of
cancers, today announced that it will present initial dose
escalation results from its Phase 1 KisMET-01 study evaluating its
investigational cMET-targeting ADC, MYTX-011, in patients with
previously treated, locally advanced or metastatic non-small cell
lung cancer (NSCLC) at the American Society of Clinical Oncology
(ASCO) Annual Meeting.
“We are pleased to present clinical data showcasing the
potential of our lead program, MYTX-011, for patients impacted by
non-small cell lung cancer,” said Gilles Gallant, BPharm, Ph.D.,
FOPQ, Chief Development Officer at Mythic Therapeutics. “The
initial dose escalation results from our ongoing KisMET-01 trial
mark an important milestone in our journey, and we look forward to
sharing these results with the scientific community at ASCO.”
Details of the presentation are as follows:
Title: MYTX-011 in patients with previously treated
locally advanced or metastatic NSCLC: Initial dose escalation
results in the phase 1 KisMET-01 study. Presenter: Melissa
Johnson, M.D., Director, Lung Cancer Research, Sarah Cannon
Research Institute Session Title: Lung Cancer—Non-Small Cell
Metastatic Session Date and Time: Monday, June 3, 1:30 -
4:30 PM CDT Location: Hall A | On Demand Poster Board
Number: 422 Published Abstract Number: 8558
About MYTX-011
MYTX-011, an investigational cMET-targeting ADC, leverages
Mythic’s innovative FateControl™ technology which is designed to
allow ADCs to actively navigate inside of cells, potentially
increasing delivery of anti-cancer agents to tumor cells with less
impact on healthy cells. This breakthrough approach takes the next
step beyond linker-payload technologies and is designed to improve
ADC efficacy against a broad set of molecular targets and patient
profiles. MYTX-011 is currently being evaluated in the Phase 1
KisMET-01 clinical trial, a first-in-human, open-label,
multi-center, dose escalation and dose expansion study enrolling
patients with locally advanced, recurrent or metastatic NSCLC
(NCT05652868).
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a
pipeline of antibody-drug conjugates (ADCs) designed to exhibit
unparalleled therapeutic index and efficacy. The Company’s
FateControl™ technology aims to enhance ADC uptake in targeted
tissues by manipulating the fate of the ADC within the cell,
thereby expanding the diseases and patient profiles that could be
treated with Mythic’s ADCs. The company’s major investors include
Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com and follow on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523096483/en/
Media Contact: Media@mythictx.com